Comparison of Repaglinide and Metformin Administered Alone or in Combination in Type 2 Diabetes

• Status: Completed
• Trial end date: 2003-02-25
• Target enrollment: 0
• Participant gender: All

Summary

This trial is conducted in Asia. The aim of this trial is to compare repaglinide and metformin administered alone or in combination in subjects with type 2 diabetes.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Metformin; Repaglinide

Criteria

Inclusion Criteria:

• Previously treated with oral hypoglycaemic agents (OHA) as monotherapy (if metformin, less than 1500 mg daily)

• Body Mass Index (BMI) of 21-35 kg/m^2

• HbA1c (glycosylated haemoglobin A1c) between 7.0-10%

Exclusion Criteria:

• Treatment with insulin within the last 3 months preceding the trial

• Uncontrolled treated or untreated hypertension (systolic blood pressure above or equal to 180 mm Hg, and/or diastolic blood pressure above 105 mm Hg)

• Participation in any other clinical trial within 30 days of screening